FOLD News and Press, Amicus Therapeutics Inc. From 02/18/21

PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences: SVB Leerink 10 th Annual Global Healthca...

PHILADELPHIA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 1, 2021 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2020. ...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks finished modestly higher Friday on light pre-holiday volume following a late-session surge led by the energy sector, as crude oil futu...

Gainers: Artelo Biosciences (ARTL) +93%. ImmunoGen (IMGN) +29%. Prothena Corporation (PRTA) +26%. NantKwest (NK) +21%. Illumina (ILMN) +19%.Losers: Amicus Therapeutics (FOLD) -33%. CollPlant Biotechnologies (CLGN) -30%. Caladrius Biosciences (CLBS) -20%. Conformis (CFMS) -16%. SQZ Biotechnolo...

Gainers: Artelo Biosciences (ARTL) +82%.Wunong Net Technology Company (WNW) +72%.China Liberal Education Holdings (CLEU) +53%.ION Geophysical (IO) +42%.Top Ships (TOPS) +42%.Seanergy Maritime Holdings (SHIP) +34%.Luokung Technology (LKCO) +29%.ImmunoGen (IMGN) +29%.EuroDry (EDRY) +28%.Lizhi (...

Amicus Therapeutics (FOLD) is extending losses in the premarket with a decline of ~24.4% following yesterday's post-market announcement of Phase 3 trial data for AT-GAA in the treatment of late-onset Pompe disease.Citing its failure to meet the primary endpoint with statis...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this event. For further details see: Amicus Therapeutics (FOLD) Presents At 17th Annual Virtual WORLDSymposium 2021 - Slideshow

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this event. For further details see: Amicus Therapeutics (FOLD) Updates on Phase 3 PROPEL Topline Results - Slideshow

Gainers: [[HX]] +16.9%. [[ASYS]] +11.8%. [[TWOU]] +8.2%. [[VITL]] +7.1%. [[OGI]] +6.3%.Losers: [[FOLD]] -19.6%. [[LLNW]] -15.5%. [[SVMK]] -13%. [[AFRM]] -8.5%. [[CRVS]] -7.4%. For further details see: OGI, TWOU, FOLD and LLNW among after-hours movers

Amicus Therapeutics (FOLD) has lost 21.3% in the post market after the company announced the topline results of its Phase 3 PROPEL pivotal trial for AT-GAA in the treatment of late-onset Pompe disease (“LOPD”).The 52-week, double-blind randomized global study evaluates...